Prot #SHP616-302: A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date3/7/16 → 3/7/21

Funding

  • PPD Development (Prot #SHP616-302 // Prot #SHP616-302)
  • Shire ViroPharma Incorporated (Prot #SHP616-302 // Prot #SHP616-302)